Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Allergan plc    AGN   IE00BY9D5467

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Allergan : Trump to keep Obama rule curbing corporate tax inversion deals

share with twitter share with LinkedIn share with facebook
share via e-mail
10/05/2017 | 04:55pm CEST
U.S. President Donald Trump departs Washington aboard Air Force One

(This October 4 story fixes comment by Organization for International Investment as referring to historically foreign-based companies in paragraph 13.)

President Donald Trump ordered a review almost six months ago of tax rules from the final months of the Obama administration, including ones to discourage companies from redomiciling abroad for tax reasons.

"Treasury plans to retain the distribution requirements under Section 385 pending enactment of tax reform," the department said in a statement, adding "these regulations are necessary to safeguard against earnings stripping."

It also said it planned to revoke and streamline some related documentation rules.

A 2011-2015 wave of inversion deals prompted Treasury to take a series of actions that culminated in an April 2016 rule release and the collapse of a $160-billion deal between U.S. drugmaker Pfizer Inc (>> Pfizer) and Ireland’s Allergan Plc (>> Allergan plc), which would have been the largest inversion ever.

Tax inversions occur when a U.S. company is acquired by a smaller foreign business from a low-tax country and adopts its domicile to reduce the combined firm’s overall U.S. tax burden.

The Section 385 rule was part of Obama's anti-inversion effort and was finalized a year ago. It was meant to combat a corporate tax-reduction technique known as earnings stripping.

Earnings stripping occurs when the U.S. subsidiary of a newly inverted company loads up on debt and avoids taxes on its domestic profits by sending them overseas to the foreign parent in the form of tax-deductible interest payments.

The Obama rule reclassified some forms of debt as equity, changing tax-exempt interest payments into taxable dividends and making earnings stripping strategies more difficult to pursue.

The Organization for International Investment (OFII), a Washington lobbying group for foreign-based companies with U.S. operations, praised the documentation portion of Treasury's latest move and criticized the retention of the rest of the Section 385 rule.

"Unfortunately, in perpetuating an unsubstantiated premise of the Obama administration, Treasury has decided to keep part of these discriminatory regulations," the group said.

Companies with historic foreign headquarters that have expanded into the United States, OFII said in a statement, "are not overleveraged, their debt levels have remained largely flat and their interest expense has declined while their investments into America’s economy have grown."

The Treasury Department said it expected a Republican proposal to overhaul the tax code would eliminate the need for anti-inversion rules. The proposal would sharply cut the corporate tax rate and end taxation of multinationals' foreign profits.

(Writing by Kevin Drawbaugh; Editing by Susan Thomas)

Stocks treated in this article : Allergan plc, Pfizer
Stocks mentioned in the article
ChangeLast1st jan.
ALLERGAN PLC -0.92% 171.79 Delayed Quote.5.02%
PFIZER -0.08% 37.33 Delayed Quote.3.06%
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ALLERGAN PLC
07/20ALLERGAN : AGN), Molecular Partners Announce Two Positive Phase 3 Clinical Trial..
07/20ALLERGAN : announce clinical trial success for abicipar
07/20ALLERGAN : abicipar pegol non-inferior to Lucentis, but increases inflammation
07/20ALLERGAN : Expands REFRESH® Portfolio With New REFRESH® REPAIR Lubricant Eye Dro..
07/20IRONWOOD PHARMACEUTICALS : Initiates Phase IIIb Study of Linaclotide in Adult Pa..
07/20ALLERGAN : Researchers from Allergan Describe Findings in Erythema (Reduction in..
07/12ALLERGAN : An Application for the Trademark "VESSILA" Has Been Filed by Allergan
07/12Novartis Becomes Latest Player to Exit Antibiotic, Antiviral Research
07/12ALLERGAN : Expands REFRESH Portfolio With New REFRESH REPAIR Lubricant Eye Drops
07/11ALLERGAN : Forbion raises EUR 270M, surpassing target for fourth fund
More news
News from SeekingAlpha
07/213 THINGS IN BIOTECH, JULY 21 : Does CTI Really Deserve To Tank? 
07/20Allergan strikes out with sovereign nation scheme to protect patents 
07/20Allergan holds off Novartis' generic version of Combigan 
07/20FDA releases updated industry guidelines for development of generic abuse-det.. 
07/20Allergan's Big Win For 12-Week Wet AMD Dosing With Abicipar May Be Enough To .. 
Financials ($)
Sales 2018 15 342 M
EBIT 2018 7 408 M
Net income 2018 -1 152 M
Debt 2018 23 173 M
Yield 2018 1,60%
P/E ratio 2018 -
P/E ratio 2019
EV / Sales 2018 5,34x
EV / Sales 2019 5,02x
Capitalization 58 790 M
Duration : Period :
Allergan plc Technical Analysis Chart | AGN | IE00BY9D5467 | 4-Traders
Technical analysis trends ALLERGAN PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 207 $
Spread / Average Target 20%
EPS Revisions
Brenton L. Saunders Chairman, President & Chief Executive Officer
Wayne R. Swanton Executive Vice President-Global Operations
Matthew M. Walsh Chief Financial Officer & Executive Vice President
C. David Nicholson Chief Research & Development Officer
Paul M. Bisaro Director
Sector and Competitors
1st jan.Capitalization (M$)
ALLERGAN PLC5.02%58 790
JOHNSON & JOHNSON-9.93%337 790
PFIZER3.06%218 540
NOVARTIS-1.75%206 705
ROCHE HOLDING LTD.-5.90%200 737
MERCK AND COMPANY11.11%168 171